Wednesday November 13, 2019

Only these 7 pasta brands have been given green chit by FSSAI after Maggi mess

0
//

9682763081_542a55fb84_o

New Delhi: Instant noodles and pastas with taste-makers of only seven companies are allowed to be sold in India, the food safety watchdog said on Monday, while also ordering tests on all approved variants and calling for the remaining “illegal” ones to be destroyed.

The seven companies that have approvals for their variants of instant noodles and pastas with taste-makers are:

FSSAI Approved Pastas & Noodles Companies Are:

  • Ruchi International (Koka)
  • CG Foods (Wai Wai)
  • Glaxosmithkline (Foodles)
  • Nestle (Maggi)
  • AA Nutrition (Yummy)
  • Indo Nisin (Top Ramen)
  • ITC (brand not specified)

“The safety of all other products in these categories has not been assessed as per the product approval procedures. As such, the same are unauthorized and illegal and cannot be intended for human consumption,” said a letter from the Food Safety and Standards Authority of India (FSSAI).

Ordering tests on all the approved varieties, the letter written by chief executive Yudhvir Singh Malik to all the commissioners of food safety said that as far as all the remaining food products are concerned, they are advised to “ensure such products are recalled, removed from the market and destroyed.”

Speaking to IANS, the top food safety officer said tests on Nestle’s Maggi and some other similar products had raised serious health concerns and thus it was thought fit to conduct tests on all similar products for which approvals had been granted.

Following tests on some samples of Maggi, the watchdog on Friday had ordered the recall of all the nine variants of Maggi pan-India, and had asked Nestle to halt its production and exports. It had also issued a similar order on Nestle’s oats noodles and taste-maker.

While Nestle continues to contend that its noodles were safe for humans and that the levels of lead were within permissible limits – as opposed to the findings of some tests that purportedly indicated otherwise, several states also became pro-active by issuing their own ban orders.

“Overseas and local manufacturers would be treated equally. More noodle brands including pasta and macaroni products will also start getting tested this week,” Malik said.

On being asked if the brand ambassadors could be taken to task, he said: “As of now, we are not considering any action.”

The regulator also detailed the process involved in the recall of food products.

“Ideally, consumers should be able to return the product at the retail outlet and get their money back if they have the bill with them. It is also Nestle’s responsibility to let the consumers return their products, if they have kept the bill with them,” he said.

The regulator also plans to post a list of all approved noodle products on its web site and advise the state authorities to test them. “We understand Delhi, Gujarat and Tamil Nadu have already started testing other brands. We will list all the approved noodle products soon.”

He further said that Nestle had been asked to give the regulator an update on compliance first after three days and then regularly until the end. “Because we understand that it could take 10 days or more, we will be taking regular progress reports from the company,” Malik said.

-IANS

Next Story

Researchers Find That Discount on Medical Drugs Can Make you Purchase Them More

The study used Canadian national pharmacy data from 2.82 million prescriptions for 89 different medications where brand-name drug discount cards were used and compared

0
Discount
While Discount cards decreased some patients' out-of-pocket costs by 7 per cent on an average, the study surprisingly found that many patients who filled prescriptions using a card were worse-off financially as a result. Pixabay

Researchers have found that brand-name Drug Discount cards are leading to higher healthcare spending in Canada.

Brand-name drug discount cards — also known as co-pay cards — are coupons offered by drug manufacturers to encourage patients to use brand-name drugs even after much cheaper generics became available.

Despite often boosting savings for customers, the study’s findings published in the Canadian Medical Association Journal show that drug discount cards actually increased private insurer costs by 46 per cent and public insurer costs by 1.3 per cent, compared to patients purchasing generics instead.

“We know that generic drugs are equally effective for the vast majority of patients. Given that, I believe these cards are leading to unjustifiable increases in health care costs,” said the study’s lead author Michael Law from the University of British Columbia in Canada.

While discount cards decreased some patients’ out-of-pocket costs by 7 per cent on an average, the study surprisingly found that many patients who filled prescriptions using a card were worse-off financially as a result.

This wasn’t the case for all drugs, but in some cases patients could pay up to $10 more out-of-pocket when using a discount card.

The study used Canadian national pharmacy data from 2.82 million prescriptions for 89 different medications where brand-name drug discount cards were used and compared the costs of these prescriptions to matched generic equivalents.

Discount
Researchers have found that brand-name Drug Discount cards are leading to higher healthcare spending in Canada. Pixabay

The researchers said that patients, their clinicians and employers should be aware of the impact that brand-name discount cards have on the healthcare system.

For example, the increased costs to private insurers will likely be passed on to the patients and their employers in the form of increased insurance premiums.

ALSO READ: Ram Mandir To Be Built In Ayodhya By 2022

“Regardless of whether they hold insurance, patients should check the relative price between brand-name drugs with a discount card and the equivalent generics at their pharmacy,” said Law. (IANS)